AKT1 and metabolic dysfunction-associated steatotic liver disease: These findings indicate that NT157 effectively negates the protective effects of JWQZG on NAFLD, providing strong evidence that JWQZG exerts its therapeutic actions through the IRS1/PI3K/AKT/GSK3β signaling pathway.